The Diagnosis and Treatment of Malaria in Pregnancy
Why Diagnosis Is Difficult
Malaria has no pathognomonic signs and can mimic a flu-like illness, so a travel history is essential in any pregnant woman with pyrexia of unknown origin. Misdiagnosis is a leading cause of preventable malaria death. Prophylaxis compliance does not exclude the diagnosis, and non-falciparum symptoms can present over a year after travel.
Diagnostic Approach
Microscopy of thick and thin blood films is the gold standard, identifying species and quantifying parasitaemia to guide treatment. Rapid diagnostic tests are useful adjuncts but less sensitive, especially at low parasitaemia (more common in pregnancy) and for P. vivax; a positive rapid test should be confirmed by microscopy. In a febrile patient, three negative films 12–24 hours apart exclude malaria. Immune women may have a negative peripheral film despite placental sequestration, so suspicion should stay high (e.g. unexplained anaemia in a recent arrival from an endemic area).
Assessing Severity
Malaria is uncomplicated (<2% parasitised red cells, no complicating features) or severe/complicated (≥2% parasitaemia, or a WHO severity feature: impaired consciousness, respiratory distress, pulmonary oedema, circulatory collapse, abnormal bleeding, jaundice, severe anaemia, hypoglycaemia, acidosis, renal impairment). Severity dictates treatment location and predicts mortality, markedly higher in pregnancy than in non-pregnant adults.
Treatment by Severity and Trimester
Treat malaria in pregnancy as an emergency: uncomplicated cases are hospitalised; severe/complicated cases need intensive/high-dependency care with multidisciplinary input (obstetrics, infectious diseases, neonatology).
- Severe/complicated malaria, any trimester: IV artesunate is treatment of choice, with a clear mortality benefit over IV quinine; it should not be withheld even in the first trimester if life-threatening. IV quinine plus clindamycin is given without delay if artesunate is unavailable, switching over once it is.
- Uncomplicated P. falciparum: oral quinine plus clindamycin is the standard first-trimester option. In the second/third trimesters, artemisinin-based combination therapy is preferred for better tolerability and compliance; atovaquone-proguanil is a further later-pregnancy option. Persistent vomiting warrants parenteral treatment.
- Non-falciparum malaria (P. vivax, P. ovale, P. malariae): chloroquine is first-line. Primaquine, needed to prevent relapse from the dormant liver stage, is avoided in pregnancy and deferred until after delivery, following G6PD testing.
Managing Complications and Obstetric Care
Quinine-induced hyperinsulinaemic hypoglycaemia can be profound, recurrent, and silent — sometimes presenting only as fetal distress — so regular glucose monitoring is essential. Pulmonary oedema, severe anaemia, and secondary sepsis are more common and more severe in pregnancy, requiring careful fluid balance, transfusion, and prompt antibiotics. Fever is treated promptly with paracetamol, since maternal pyrexia is linked to preterm labour and fetal distress. Uncomplicated malaria is not an indication for induction of labour.
High-Yield Exam Points
- Three negative blood films 12–24 hours apart exclude malaria; microscopy is the gold standard, ahead of rapid diagnostic tests.
- Severe malaria = ≥2% parasitaemia or a WHO severity feature (impaired consciousness, pulmonary oedema, shock, severe anaemia, hypoglycaemia, acidosis, renal impairment).
- IV artesunate is first-line for severe malaria in any trimester, ahead of IV quinine, for a clear mortality benefit.
- Quinine plus clindamycin is the traditional first-trimester choice for uncomplicated P. falciparum; artemisinin-based combination therapy preferred second/third trimester.
- Chloroquine treats non-falciparum malaria; primaquine is contraindicated in pregnancy, deferred postpartum after G6PD testing.
- Quinine causes hyperinsulinaemic hypoglycaemia that can be profound and late-presenting — monitor glucose regularly; uncomplicated malaria alone is not an indication to induce labour.
Source: RCOG Green-top Guideline No. 54b (First published April 2010 (first edition), not revised since. The ACMP has agreed to take over and update it — treat drug-availability/licensing detail as potentially superseded by current UKHSA/ACMP guidance.)
Read the original on rcog.org.uk
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).